Predictive Value of Cardiopulmonary Exercise Testing Parameters in Ambulatory Advanced Heart Failure.

ambulatory heart failure cardiac transplant cardiopulmonary exercise stress test mechanical circulatory support predictors

Journal

JACC. Heart failure
ISSN: 2213-1787
Titre abrégé: JACC Heart Fail
Pays: United States
ID NLM: 101598241

Informations de publication

Date de publication:
03 2021
Historique:
received: 10 08 2020
revised: 03 11 2020
accepted: 12 11 2020
pubmed: 8 2 2021
medline: 25 2 2023
entrez: 7 2 2021
Statut: ppublish

Résumé

This study sought to determine cardiopulmonary exercise (CPX) predictors of the combined outcome of durable mechanical circulatory support (MCS), transplantation, or death at 1 year among patients with ambulatory advanced heart failure (HF). Optimal CPX predictors of outcomes in contemporary ambulatory advanced HF patients are unclear. REVIVAL (Registry Evaluation of Vital Information for ventricular assist devices [VADs] in Ambulatory Life) enrolled 400 systolic HF patients, INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) profiles 4-7. CPX was performed by 273 subjects 2 ± 1 months after study enrollment. Discriminative power of maximal (peak oxygen consumption [peak VO At 1 year, there were 39 events (6 transplants, 15 deaths, 18 MCS implantations). Peak VO Among patients with ambulatory advanced HF, the strongest maximal and submaximal CPX predictor of MCS implantation, transplantation, or death at 1 year were CP and VE/VCO

Sections du résumé

OBJECTIVES
This study sought to determine cardiopulmonary exercise (CPX) predictors of the combined outcome of durable mechanical circulatory support (MCS), transplantation, or death at 1 year among patients with ambulatory advanced heart failure (HF).
BACKGROUND
Optimal CPX predictors of outcomes in contemporary ambulatory advanced HF patients are unclear.
METHODS
REVIVAL (Registry Evaluation of Vital Information for ventricular assist devices [VADs] in Ambulatory Life) enrolled 400 systolic HF patients, INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) profiles 4-7. CPX was performed by 273 subjects 2 ± 1 months after study enrollment. Discriminative power of maximal (peak oxygen consumption [peak VO
RESULTS
At 1 year, there were 39 events (6 transplants, 15 deaths, 18 MCS implantations). Peak VO
CONCLUSIONS
Among patients with ambulatory advanced HF, the strongest maximal and submaximal CPX predictor of MCS implantation, transplantation, or death at 1 year were CP and VE/VCO

Identifiants

pubmed: 33549559
pii: S2213-1779(20)30703-4
doi: 10.1016/j.jchf.2020.11.008
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT01369407']

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

226-236

Subventions

Organisme : NHLBI NIH HHS
ID : HHSN268201100026C
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002240
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL132154
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding support and Author Disclosures Supported by U.S. National Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI) contract HHSN268201100026C, and National Center for Advancing Translational Sciences grant UL1TR002240. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health, or the US Department of Health and Human Services. Dr. Lanfear has received research grants from NHLBI (R01HL132154), Amgen, Bayer, and Janssen; and is a consultant for Amgen, Janssen, Ortho Diagnostics, and Novartis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Anuradha Lala (A)

Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Keyur B Shah (KB)

Department of Medicine, Division of Cardiology, Virginia Commonwealth University, Richmond, Virginia, USA.

David E Lanfear (DE)

Heart and Vascular Institute, Henry Ford Hospital, Detroit, Michigan, USA.

Jennifer T Thibodeau (JT)

Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Maryse Palardy (M)

Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA.

Amrut V Ambardekar (AV)

University of Colorado, Boulder, Colorado, USA.

Dennis M McNamara (DM)

Department of Medicine, Division of Cardiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Wendy C Taddei-Peters (WC)

Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA.

J Timothy Baldwin (JT)

Michigan State University, East Lansing, Michigan, USA.

Neal Jeffries (N)

Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, Maryland, USA.

Shokoufeh Khalatbari (S)

Michigan Institute for Clinical and Health Research, University of Michigan, Ann Arbor, Michigan, USA.

Cathie Spino (C)

Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA.

Blair Richards (B)

Michigan Institute for Clinical and Health Research, University of Michigan, Ann Arbor, Michigan, USA.

Douglas L Mann (DL)

Cardiovascular Division, Washington University School of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.

Garrick C Stewart (GC)

Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Keith D Aaronson (KD)

Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA.

Donna M Mancini (DM)

Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: donna.mancini@mountsinai.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH